title: Minimizing graft rejection in allogeneic T cell-depleted bone marrow transplantation.
abstract: Between October 1991 and May 1994, 42 patients were treated with cyclophosphamide, thiotepa, and total body irradiation followed by an allogeneic transplantation of marrow depleted of T cells with soybean agglutinin and E-rosetting. Patients included in this study had acute myelogenous leukemia (13), chronic myelogenous leukemia (12), acute lymphocytic leukemia (nine), Hodgkin's disease or non-Hodgkin's lymphoma (four), multiple myeloma (three), or myelodysplastic syndrome (one). The mean age was 34 (range 8 to 51 years). Nineteen patients had a matched sibling donor and 18 received marrow from 6/6 matched unrelated donors while five received transplants from unrelated donors disparate at one DR locus (5/6 match). Time to granulocyte engraftment (AGC > or = 500/mm3) occurred at a mean of 16.5 days for related and 11.4 days for unrelated transplant recipients, and was related to the increased use of G-CSF in the unrelated population. There was no correlation with number of mononuclear cells, T cells, or CD34-positive cells infused, the rate of engraftment or the incidence of transplant complications. Multivariate analysis determined that G-CSF administration and a diagnosis other than ALL were the only factors associated with a faster rate of engraftment. Patients receiving unrelated donor transplants, those with ALL, or those who had a low T cell number infused (< or = 8.0 x 10(3) cells/kg) experienced delayed hospital discharge. The regimen resulted in excellent rates of engraftment (95.2%) with only one failure to engraft and one graft rejection. The incidence of grade III-IV acute graft-versus-host disease was 0% with sibling and 26.1% with unrelated donors. There were no cases of veno-occlusive disease. Fifty percent of patients are alive with a mean follow-up of 26.4 months. We conclude that this regimen is well tolerated and results in excellent engraftment with a low incidence of severe graft-versus-host disease and few therapy-related toxicities.
authors.affiliation: Division of Hematology/Oncology, Indiana University School of Medicine, Indianapolis, USA.
authors.forename: J P
authors.initials: JP
authors.lastname: Rigden
authors.forename: K
authors.initials: K
authors.lastname: Cornetta
authors.forename: E F
authors.initials: EF
authors.lastname: Srour
authors.forename: M
authors.initials: M
authors.lastname: Hanna
authors.forename: E R
authors.initials: ER
authors.lastname: Broun
authors.forename: R
authors.initials: R
authors.lastname: Hromas
authors.forename: J
authors.initials: J
authors.lastname: Baute
authors.forename: J
authors.initials: J
authors.lastname: Hilton
authors.forename: E
authors.initials: E
authors.lastname: Cox
authors.forename: L
authors.initials: L
authors.lastname: Rubin
authors.forename: R
authors.initials: R
authors.lastname: Gonin
authors.forename: G
authors.initials: G
authors.lastname: Tricot
mesh_terms: D000293:Adolescent; D000328:Adult; D016026:Bone Marrow Transplantation / Q000379:methods*; D002648:Child; D005260:Female; D006084:Graft Rejection / Q000517:prevention & control*; D006402:Hematologic Diseases / Q000628:therapy*; D006801:Humans; D008212:Lymphocyte Depletion; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000628:therapy*; D013601:T-Lymphocytes